DATE: August 31, 2016
Who is Our Client?
- Founded in 2000, Thompson Street Capital Partners is a private equity firm that has managed over $1.5 billion in private equity capital.
- From its headquarters in St. Louis, MO, Thompson Street has completed in excess of 100 acquisitions in more than 35 industries.
- Thompson Street brings broad financial and operational knowledge to its portfolio companies to accelerate growth — both organically and through acquisitions.
- In May 2015, Nolan advised Thompson Street in its acquisition of Microbiology Research Associate(MRA), based in Acton, MA, outside of Boston.
- MRA is an FDA-registered, cGMP contract laboratory specializing in product testing, validation and contamination control remediation for the Biopharma, Medical Device, Pharmacy and Cosmetic industries.
Why Did Thompson Street Capital Partners Hire Nolan?
- Following the acquisition of MRA, Nolan was engaged by Thompson Street to find add-on acquisitions for MRA in the Contract Research Organization (CRO) space.
- Management and Thompson Street were seeking CROs providing microbiology testing, pre-clinical lab research, drug trial logistics, commercialized drug manufacturing, compounding pharmacy support and anti-microbial testing (EPA, medical device, etc.).
What Value Did Nolan Deliver?
- To meet Thompson Street’s top objectives, Nolan investigated the market for applicable MRA add-on opportunities, and presented those that best aligned with the investment goals of Thompson Street.
- Accuratus Lab Services, headquartered in Eagan, MN, is a premier contract anti-microbial testing laboratory and expert partner to the developers, manufacturers and users of anti-microbial pesticide and biocide products and medical devices.
- Accuratus was a division of Avista Pharma Solutions, Inc., a Contract Development and Manufacturing Organization (CDMO) with facilities in Durham, NC, Longmont, CO and Agawam, MA.
- Accuratus was acquired by MRA/Thompson Street in September 2016, enabling the expansion of MRA’s capabilities into anti-microbial testing in the EPA and medical device segments.
